HWPC withdraws the registration application for Arolol hydrochloride tablets
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, HWPC announced that the company recently received the "Notice of Termination of Drug Registration Application" approved and issued by the National Medical Products Administration, agreeing to the company's withdrawal of the registration application for Arolol Hydrochloride Tablets. Arolol Hydrochloride Tablets are mainly used for the treatment of primary hypertension (mild to moderate), angina pectoris, tachyarrhythmia, and essential tremor
According to the Zhitong Finance APP, HWPC (688799.SH) announced that it recently received the "Notice of Termination of Drug Registration Application" approved and issued by the National Medical Products Administration, agreeing to the company's withdrawal of the registration application for Arolol Hydrochloride Tablets.
Arolol Hydrochloride Tablets are mainly used for the treatment of primary hypertension (mild to moderate), angina pectoris, tachyarrhythmia, and essential tremor